Grass-pollen allergy immunotherapy sublingual - Lofarma

Drug Profile

Grass-pollen allergy immunotherapy sublingual - Lofarma

Alternative Names: LAIS® Grass Tablets

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lofarma S.p.A
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 06 Sep 2017 Phase III development is ongoing Italy, Hungary and Germany (EudraCT2014-004431-38) (EudraCT2012-004916-79)
  • 25 Mar 2015 Phase-III clinical trials in Allergic rhinoconjunctivitis in Hungary and Italy (Sublingual) (EudraCT2014-004431-38)
  • 26 Feb 2013 Phase-III clinical trials in Allergic rhinoconjunctivitis in Germany (Sublingual) (EudraCT2012-004916-79)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top